Coeptis Therapeutics (COEP) Competitors $0.14 0.00 (-2.08%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends COEP vs. RNXT, PMN, LIAN, NXTC, FBRX, DRRX, KALA, DARE, LGVN, and LPCNShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include RenovoRx (RNXT), ProMIS Neurosciences (PMN), LianBio (LIAN), NextCure (NXTC), Forte Biosciences (FBRX), DURECT (DRRX), KALA BIO (KALA), Daré Bioscience (DARE), Longeveron (LGVN), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. RenovoRx ProMIS Neurosciences LianBio NextCure Forte Biosciences DURECT KALA BIO Daré Bioscience Longeveron Lipocine RenovoRx (NASDAQ:RNXT) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking. Do institutionals & insiders have more ownership in RNXT or COEP? 3.1% of RenovoRx shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 7.1% of RenovoRx shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer RNXT or COEP? In the previous week, RenovoRx's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score. Company Overall Sentiment RenovoRx Neutral Coeptis Therapeutics Neutral Which has more risk & volatility, RNXT or COEP? RenovoRx has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.9, suggesting that its stock price is 190% less volatile than the S&P 500. Do analysts rate RNXT or COEP? RenovoRx currently has a consensus price target of $6.50, suggesting a potential upside of 420.00%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts clearly believe RenovoRx is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer RNXT or COEP? RenovoRx received 4 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 47.37% of users gave RenovoRx an outperform vote. CompanyUnderperformOutperformRenovoRxOutperform Votes947.37% Underperform Votes1052.63% Coeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Is RNXT or COEP more profitable? RenovoRx's return on equity of -205.96% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -205.96% -110.01% Coeptis Therapeutics N/A -1,094.50%-219.97% Which has higher earnings & valuation, RNXT or COEP? RenovoRx has higher earnings, but lower revenue than Coeptis Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRxN/AN/A-$10.23M-$0.57-2.19Coeptis Therapeutics$80K72.73-$21.27M-$0.29-0.49 SummaryRenovoRx beats Coeptis Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.82M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.4945.9489.7417.16Price / Sales72.73415.011,117.09117.04Price / CashN/A182.1043.1037.86Price / Book7.083.894.784.78Net Income-$21.27M-$42.21M$120.31M$225.60M7 Day Performance-20.46%-2.15%-1.92%-1.23%1 Month Performance-27.29%1.73%13.65%0.46%1 Year Performance-83.22%16.36%28.34%15.24% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.3751 of 5 stars$0.14-2.1%N/A-83.9%$5.82M$80,000.00-0.492Gap DownRNXTRenovoRx1.2324 of 5 stars$1.27-1.1%$6.50+413.5%+47.1%$30.38MN/A-2.256Positive NewsGap UpPMNProMIS Neurosciences1.0623 of 5 stars$0.91-2.1%N/A-20.0%$29.75M$10,000.00-9.306Positive NewsLIANLianBioN/A$0.27flat$3.50+1,194.4%-94.2%$29.22MN/A-0.33110NXTCNextCure4.2217 of 5 stars$1.02-5.6%$4.00+292.2%-13.4%$28.57MN/A-0.5290Positive NewsFBRXForte Biosciences1.6802 of 5 stars$19.53-15.6%$23.58+20.8%+65,414.9%$28.51MN/A-1.315DRRXDURECT2.6267 of 5 stars$0.91+21.4%$5.00+449.3%+83.5%$28.26M$8.59M-1.3980Analyst ForecastNews CoverageKALAKALA BIO3.8466 of 5 stars$6.11-1.1%$15.00+145.5%-14.8%$28.17M$3.89M-0.5030Gap DownDAREDaré Bioscience1.5891 of 5 stars$3.20+0.6%$24.00+650.0%-28.4%$27.84M$1.88M-5.3930Analyst ForecastGap DownLGVNLongeveron3.4375 of 5 stars$1.83-1.6%$8.67+373.6%-86.8%$27.15M$1.89M-0.3023LPCNLipocine1.5291 of 5 stars$4.97-1.0%$10.00+101.2%+66.5%$26.58M$7.92M-6.6110News Coverage Related Companies and Tools Related Companies RenovoRx Alternatives ProMIS Neurosciences Alternatives LianBio Alternatives NextCure Alternatives Forte Biosciences Alternatives DURECT Alternatives KALA BIO Alternatives Daré Bioscience Alternatives Longeveron Alternatives Lipocine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COEP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
